AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00686179
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00686504
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9
- Registration Number
- NCT00686413
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
AZD6140 Oral Contraceptive Interaction Study
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00685906
- Locations
- 🇺🇸
Research Site, Miami, Florida, United States
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
Phase 2
Completed
- Conditions
- Nonvalvular Atrial Fibrillation
- Interventions
- Drug: Vitamin-K antagonist at INR 2-3
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1084
- Registration Number
- NCT00684307
Survey of Lipid Goal Attainment and Mortality in Patients With High Cardiovascular Risk in Thailand
Completed
- Conditions
- Dyslipidemia
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2011-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1240
- Registration Number
- NCT00684151
- Locations
- 🇹🇭
Research Site, Maung, Uttaradit, Thailand
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT00684502
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Drug Interaction Study Between AZD3355 and Nexium
Phase 1
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00684190
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
- Conditions
- Non Small Cell Lung CancerCancer of the Head and Neck
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00684385
- Locations
- 🇬🇧
Research Site, Newcastle-upon-Tyne, United Kingdom
Add-on to Thiazolidinedione (TZD) Failures
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 972
- Registration Number
- NCT00683878
- Locations
- 🇺🇸
Diabetes Research Center, Tustin, California, United States
🇺🇸Endocrine Research Associates, Jackson, Mississippi, United States
🇺🇸Dallas Diabetes & Endocrine Center, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath